Tumor Abnormal Protein as a Novel Biomarker in Papillary Thyroid Carcinoma

Liu, Zhinan; Cai, Jing-Sheng; Yu, Yue; Fang, Haisheng; Si, Yan; Jankee, Jinista J; Shen, Mingqiang

doi:10.7754/clin.lab.2016.160903

Cited by 13 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,20 Apart from lung cancer, the existence of TAP expression is evident in the stomach, colorectal, thyroid, and bladder tumors. [9][10][11][12]21 Our research findings add to the general overview of TAP's role in a tumor's development and progression.…”

Section: Discussionmentioning

confidence: 94%

“…Recent studies have collected evidence on the critical role that TAP plays in the development and progression of cancer, as well as the regulation of cell proliferation, apoptosis, differentiation, and development. [7][8][9] In gastric cancer patients, the upregulation of TAP was significant compared to healthy volunteers. Also, progression-free survival (PFS) is evident among patients with high TAP levels.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

<p>Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer</p>

Cheng

Chen

Zang

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: The most common cancer among humans is lung cancer. Non-small cell lung cancer (NSCLC) comprises the majority of these cases. In the development and progression of cancers across the spectrum, tumor abnormal protein (TAP) plays crucial roles. Additionally, in the advancement of the bladder and colorectal cancers, the involvement of glycoproteins like TAP is present. However, it is worth noting that current literature has yet to clarify the clinical significance of the TAP in NSCLC. Methods: In the present study, to evaluate the relative level of TAP, we utilized a TAP detection agent in 154 cases of NSCLC and normal patients who underwent surgical resection anytime from March 2013 to January 2019 at the People's Hospital of Chizhou. Results: Our results demonstrated that in NSCLC patients, the expression level of TAP was significantly higher than in normal patients. Moreover, after surgery, TAP expression was significantly downregulated in NSCLC patients. TAP expression is associated with an array of factors, which include the patient's sex, history of smoking use, tumor size, pTNM, distant cancer, metastasis of lymph nodes, invasive and aggressive indicator pleural invasion, and differentiation degree of NSCLC. Additionally, TAP has no association with the patient's age, history of drinking, location of the tumor, hypertension, and diabetes. In NSCLC patients, a poor overall survival rate within 5 years is significantly correlated with the increased TAP expression. For NSCLC patients, an independent prognostic factor is the TAP, which is confirmed using the multivariate survival analysis. Conclusion: In the malignant progression of NSCLC, our results demonstrate how the promoting role of the upregulated TAP expression takes place. Hence, a therapeutic aim for NSCLC and a potential biomarker for NSCLC progress is a TAP.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 98%

<p>Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer</p>

Cheng

Chen

Zang

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Approximately 70% of proteins in vivo have glycosylation modifications [8]. It has been reported that TAP plays an important role in improving the diagnosis of cancerous tumors, such as bladder, gastric, thyroid, colorectal, and endometrial cancers [9][10][11][12][13].…”

Section: Discussionmentioning

confidence: 99%

“…As the number of cancer cells reaches 100,000 and above [24][25][26], abnormal glycoprotein can be detected in peripheral blood, and its presence indirectly reflects the degree of malignancy of the carcinoma. Since its discovery by Soviet scholars, TAP has been widely used in cancer screening, early diagnosis and evaluation of therapeutic effects on certain tumors [13]. Sun et al found that in patients with malignant tumors of the digestive tract, negative TAP expression in the peripheral blood indicated the complete elimination of tumors.…”

Section: Diagnostic Efficacy Of Tap For Rccmentioning

confidence: 99%

The use of TAP for the primary diagnosis of renal cell carcinoma

Jiang

Liu

et al. 2019

Preprint

View full text Add to dashboard Cite

Objective To study the value of TAP expression in peripheral blood for early diagnosis of renal cell carcinoma. Materials and Methods TAP expression was analyzed in the peripheral blood of 45 patients with renal cell carcinoma, 32 patients with benign renal lesions and 42 healthy patients. An analysis of the relationship between TAP expression and the clinicopathological features in renal cell carcinoma was performed; the ROC curve was used to evaluate the diagnostic efficacy of TAP detection for renal cell carcinoma diagnosis. Results TAP levels were significantly higher in RCC patients than in patients with nonneoplastic diseases. We also found that the rate of positive TAP expression in the peripheral blood of the renal cell carcinoma group showed no significant difference when evaluated by age, sex, histological grade, tumor stage, tumor size or tumor location (P > 0.05). The area under the ROC curve was 0.92 (95% CI: 0.82-0.95), and the sensitivity and specificity in the diagnosis of RCC was 73% and 91%, respectively. Conclusions The expression of TAP in peripheral blood of patients with renal cell carcinoma was significantly higher than that in nonneoplastic patients, which may provide an effective means of primary diagnosis for renal cell carcinoma

show abstract

“…Current studies have indicated the involvement of various molecular events in the deterioration of PTC (5,6), including BRAF and RAS mutations, rearrangements of RET protooncogene and the excessive activation of the mitogen-activated protein kinase signal transduction pathway (7)(8)(9)(10). To date, multiple microRNAs (miRs) and long non-coding RNAs (lncRNAs) have been identified as potential molecular biomarkers, including miR-146b-5p and lncRNA HOTTIP, which have been confirmed to participate in the invasion and metastasis of PTC (11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Integrated bioinformatics analysis of the association between apolipoprotein E expression and patient prognosis in papillary thyroid carcinoma

et al. 2020

View full text Add to dashboard Cite

The prognosis of most patients with papillary thyroid carcinoma (PTC) is excellent despite some cases of tumor progression or relapse. The present study was designed to reveal possible prognostic risk indicators for PTC. Differentially expressed genes (DEGs) extracted from 4 Gene Expression Omnibus (GEO) cohorts were subjected to functional enrichment analyses by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway analysis. A dataset from The Cancer Genome Atlas (TCGA) was obtained to filter and validate significant genes using cytoHubba, followed by analysis of their association with clinicopathological characteristics and prognosis. In total, 240 DEGs were identified after data preprocessing. These DEGs were enriched in 'intracellular redox equilibrium', 'release of exosome', 'cell adhesion', 'regulation of extracellular matrix', 'collagen binding' and 'energy metabolism' based on GO analysis which including cellular component, molecular function and biological process. KEGG pathway analysis revealed that the DEGs were enriched in thyroid hormone synthesis, pathways in cancer, focal adhesion, metabolic pathways, apoptosis, PPAR signaling pathway and PI3K/AKT signaling pathway. Using cytoHubba, the following hub genes were identified: Apolipoprotein E (APOE); hemoglobin subunit α1 (HBA1); angiotensin II receptor 1 (AGTR1); collagen I α1 (COL1A1); galectin 3 (LGALS3) and TIMP metallopeptidase inhibitor 1 (TIMP1). The expression of these genes was found to be consistent in TCGA datasets. Kaplan-Meier analysis revealed that APOE was significantly associated with overall survival (P=0.00067) and disease free survival (P=0.00220). Additionally, low expression of APOE was significantly associated with older age (P<0.001) and higher TNM stage (P<0.001) compared with the high expression group. Therefore, APOE may function as a predictive risk indicator for progression as well as prognosis of PTC.

show abstract

Tumor Abnormal Protein as a Novel Biomarker in Papillary Thyroid Carcinoma

Abstract: TAP may be a novel biomarker for PTC and be useful in the adjuvant diagnosis of PTC.

Cited by 13 publications

References 0 publications

<p>Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer</p>

<p>Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer</p>

The use of TAP for the primary diagnosis of renal cell carcinoma

Integrated bioinformatics analysis of the association between apolipoprotein E expression and patient prognosis in papillary thyroid carcinoma

Contact Info

Product

Resources

About